Patent · US Active

PD-1 antibody formulation

US11130809B2 · kind B2 · utility

0Cited by
0References
14Claims
0Family size

Assignee

Inventors

Key dates

Filing dateJul 17, 2017
Grant dateSep 28, 2021
Priority date—
Expiry dateSep 10, 2038

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC07K2317/94
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

Provided herein are pharmaceutical formulations for anti-PD-1 antibodies.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.